Kate Bechtold | Senior Director, Investor Relations |
Liz Barrett | President and Chief Executive Officer |
Mark Schoenberg | Chief Medical Officer |
Peter Pfreundschuh | Chief Financial Officer |
Jeff Bova | Senior Vice President, Commercial |
Derek Archila | Stifel Nicolaus |
Chris Howerton | Jefferies |
Paul Choi | Goldman Sachs |
Ram Selvaraju | H.C. Wainwright & Co. |
Matthew Kaplan | Ladenburg Thalmann |
Maria Barbera | National Securities |
Good morning, ladies and gentlemen, thank you for standing by, and welcome to UroGen Pharma’s Fourth Quarter and Full-Year 2019 Financial Results and Business Update Conference Call.
It is now my pleasure to turn the call over to Kate Bechtold, Senior Director of Investor Relations for UroGen Pharma. Please go ahead.
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma’s fourth quarter and full-year 2019 financial results and business update conference call.